Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: A cost effectiveness analysis

Pediatric Blood and Cancer

Volumn 62, Issue 10, 2015, Pages 1862-1864

  Cunningham Myrie, Colette ^a   Abdulkadri, Abdullahi ^a   Waugh, Andre ^a   Bortolusso Ali, Susanna ^a   King, Lesley Gaye ^a   Knight Madden, Jennifer ^a   Reid, Marvin ^a  

^a UNIVERSITY OF THE WEST INDIES   (Jamaica)

Author keywords

Neurology sickle cell; Outcomes research; Sickle cell disease

Indexed keywords

HYDROXYUREA; ANTISICKLING AGENT;

ARTICLE; CEREBROVASCULAR ACCIDENT; CHILD; CHILDHOOD MORTALITY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DRUG SAFETY; FEMALE; HEALTH CARE COST; HOSPITALIZATION COST; HUMAN; LENGTH OF STAY; MALE; PEDIATRICS; PRIORITY JOURNAL; RECURRENT DISEASE; SECONDARY PREVENTION; SICKLE CELL ANEMIA; TREATMENT OUTCOME; TREATMENT RESPONSE; ANEMIA, SICKLE CELL; COMPLICATION; COST BENEFIT ANALYSIS; ECONOMICS; JAMAICA; STROKE;

ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; CHILD; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; FEMALE; HUMANS; HYDROXYUREA; JAMAICA; MALE; RECURRENCE; STROKE;

EID: 84939564924     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25563     Document Type: Article

References (18)

1. Segal JB, Strouse JJ, Beach MC, Haywood C, Witkop C, Park H, Wilson RF, Bass EB, Lanzkron S. Hydroxyurea for the treatment of sickle cell disease. Evid Rep Technol Assess 2008; 165:1-95.
2. Ali SB, Moosang M, King L, Knight-Madden J, Reid M. Stroke recurrence in children with sickle cell disease treated with hydroxyurea following first clinical stroke. Am J Hematol 2011; 86:846-850.
3. Thornburg CD, Calatroni A, Panepinto JA. Differences in health-related quality of life in children with sickle cell disease receiving hydroxyurea. J Pediatr Hematol Oncol 2011; 33:251-254.
4. Ohene-Frempong K, Weiner SJ, Sleeper LA, Miller ST, Embury S, Moohr JW, Wethers DL, Pegelow CH, Gill FM. Cerebrovascular accidents in sickle cell disease: Rates and risk factors. Blood 1998; 91:288-294.
5. Balkaran B, Char G, Morris JS, Thomas PW, Serjeant BE, Serjeant GR. Stroke in a cohort of patients with homozygous sickle cell disease. The Journal of Pediatrics 1992; 120:360-366.
6. Morton CT, Key NS. Stroke in sickle cell disease. Seminars in cerebrovascular diseases and stroke 2002; 2:143-150
7. Ware RE, Helms RW, Investigators SW. Stroke with transfusions changing to hydroxyurea (SWiTCH). Blood 2012; 119:3925-3932.
8. Moore RD, Charache S, Terrin ML, Barton FB, Ballas SK. Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Am J Hematol 2000; 64:26-31.
9. Stallworth JR, Jerrell JM, Tripathi A. Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease. Am J Hematol 2010; 85:795-797.
10. Nottage KA, Hankins JS, Smeltzer M, Mzayek F, Wang WC, Aygun B, Gurney JG. Hydroxyurea use and hospitalization trends in a comprehensive pediatric sickle cell program. PloS ONE 2077; 8:e72077.
11. Wang WC, Oyeku SO, Luo Z, Boulet SL, Miller ST, Casella JF, Fish B, Thompson BW, Grosse SD, Investigators BH. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics 2013; 132:677-683.
12. Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood 2010; 115:5300-5311.
13. Platt OS. Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med 2008; 358:1362-1369.
14. Mulaku M, Opiyo N, Karumbi J, Kitonyi G, Thoithi G, English M. Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries. Arch Dis Child 2013; 98:908-914.
15. Bilenker JH, Weller WE, Shaffer TJ, Dover GJ, Anderson GF. The costs of children with sickle cell anemia: Preparing for managed care. J Pediatr Hematol Oncol 1998; 20:528-533.
16. Raphael JL, Dietrich CL, Whitmire D, Mahoney DH, Mueller BU, Giardino AP. Healthcare utilization and expenditures for low income children with sickle cell disease. Pediatr Blood Cancer 2009; 52:263-267.
17. Nevin J, Myers L, Osunkwo I, Kanter J. A retrospective study to assess the utility of frequent laboratory monitoring of pediatric patients with sickle cell disease on hydroxyurea. J Pediatr Hematol Oncol 2014; 36:e180-e184.
18. Cherry MG, Greenhalgh J, Osipenko L, Venkatachalam M, Boland A, Dundar Y, Marsh K, Dickson R, Rees DC. The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: A systematic review and economic evaluation. Health Technol Assess 2012; 16:1-129.